Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Edelman Website

Daniel C. Edelman, Ph.D.

Portait Photo of Daniel Edelman
Genetics Branch
Facility Head
Center for Cancer Research
National Cancer Institute
Clinical Molecular Profiling Core
37 Convent Dr., Room 6040
Bethesda, MD 20892-4605
Phone:  
301-435-2891
Fax:  
301-480-1918
E-Mail:  
edelmand@mail.nih.gov

Research

The CMPC Mission
By developing and implementing state of the art genomic technologies, the Clinical Molecular Profiling Core maximizes the clinical benefits and biological insights derived from the analysis of biospecimens obtained from National Cancer Institutes clinical trials.

Core Activities: Research & Clinical (CLIA)
The Clinical Molecular Profiling Core (CMPC) was established in 2006 under the auspices of the Center for Cancer Research, National Cancer Institute. The vision was to create a robust and scientifically advanced laboratory program that would bring the tools of genome technology to bear on NCI intramural clinical trials. It has become increasingly recognized in this new era of targeted therapies that critical aspects of tumor biology can be elucidated by analysis of the cancer genome. Clinical trial outcomes could be better characterized with analysis of cancer genomes with respect to properties such as copy number aberrations, epigenomics, mRNA, and micro-RNA profiles. Importantly, these data also can drive discovery of new tumor subsets and therapeutically relevant genomic features which can lead to personalized cancer treatments. The CMPC creates the opportunity to make the necessary molecular analyses available to any NCI clinical investigator. Being a CLIA compliant laboratory magnifies our impact which allows us to raise the bar on personalized cancer medicine. In order to keep CMPC technologies at the state-of-the-art, the Core includes a technology research and development component in its mission to innovate and develop new cutting edge applications that would widen the applicability of genome technologies to clinically accessible samples.

This page was last updated on 9/11/2013.